Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on 13 August, ....

3{) Omkar Phavmachem Led. Date: 13/08/2026 BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 Sub: - Outcome of the Board Meeting held on 13" August, 2026 Company Scrip Code: 532167 Dear Sir, Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on 13" August, 2026 has considered and approved the following business: 1. Unaudited Financial Results of the Company alongwith Limited Review Report for the quarter ended on 30" June, 2026. The aforesaid board meeting commenced at 03:30 P.M. and concluded at 04:10 P.M. This is for your information and record. Thanking You, Yours faithfully, For Omkar Pharmachem Limited DIN: 03255804 Address: Ward No-03, Nangal Chaudhry, Narnaul, Mahendragarh, Haryana-123023 Encl: a/a Reg. Off.: 310, Wall Street-1, Near Gujarat College Cross Road, Ellisbridge Ahmedabad-380006, GJ, Ph.: 9711811163 CIN: L83000GJ1985PLC025276, Email: investors.opl@gmail.com, Website: www.omkarpharmachem co.in WIDRSC DIFALR: e & cO. 507, Mauryansh Elanza, Nr. Parekhs Hospital, Shyamal Cross Road,| Email: info@drscindia.com TRUST l ETH‘CSIKNOW'—EDGE Satellite, Ahmedabad - 380 015. (M) 94093 68999 (O) 079 - 40053654. | Web : www.drscindia.com Limited Review Report to the Board of Directors of Omkar Pharmachem Limited for quarter ended on 30" June, 2026 We have reviewed the accompanying statement of unaudited financial results of Omkar Pharmachem Limited for the quarter ended on 30 June, 2026. This statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and; thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information Tegs ired to be disclosed in terms of Regulation 33 of the SEBI (Listing O Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For, Dipal R. Shah & Co. Ghartered Accountants RN 126576W Place: Ahmedabad Date : 13/08/2026 Partner UDIN: 26119628MDSUMC7339 ~3s9 Owmkar Pharmachem L. Statement of Standalone Unaudited Financial Results for the Quarter Ended on 30th June 2026 (Rs. in lakh except per share data)| Sr. Particulars Quarter Ended on Fiancial Year No. ended on 30-06-2026 | 31-03-2026 | 30-06-2025 | 31-03-2026 (Unaudited) |_(Audited) | (Unaudited) | (Audited) Part-1 1 [Income from operations a)Net Sales/ Income from Operations 0.00 0.00 0.00 0.00} bJOther Operating Income 9.00 9.00, 1350 46.50 900 9.00 1350 46.50) 2 |Other Tncome 000 030 000 074 3 [Net Total income 9.00 9.30 13.50 47.24) 4 |Expenses a) Cost of material consumed 000 0.00) 000 0.00 b) Purchase of Stock-in-trade 000 0.00 000 0.00) ¢) Changes in Inventories of Finished Goods, WIP and Stock-in trade 000 0.00) 0.00 0.00) d) Employee benefits expenses 514 514 493 20.86) ) Finance Cost 000 0.00) 0.00 021 f) Depreciation and Amortization Expenses 004 0.08] 0.08 033 2) Other Expenses 482 213 491 9.56 Total Expenses 10.00 7.35, 9.92 30.96 5 |P rofit(Loss) before exceptional items and tax(3-4) (1.00)) i 358 icai 6 [Exceptional items 0.00 0.00 0.00 000 7 |Profit(Loss) from before Tax( 56) (1.00) 195 358 1628 8 [Tax Expense 0.00 045 092 410 o [Profit(Loss) for the period (7-8) (1.00) 1.50 2.66 1218 10 [Other Comprehensive Income (Expense) 000| 270843 0.00 270843 11| Total Comprehensive Income for the period (9210) o0 270993 2.66 272061 12 [Paid up Equity Share Capital (Face Value Rs. 10/~ cach) 1008.37) 100837 1008.37) 1008.37) 13 |Other equity (52.82)] (52.82)] 14 |Eaming Per Share(before & afler extraordinary items)oRsf. 10 cach)(not annualised) Basic and ©0.0099)] 0.0149 0.0264 0.1208 diluted R Notes 1. The above results have been reviewed by the audit committee & approved by the Board of Dircctors at thei respective meeting held on 13th August 2026 2.Corrosponding previous period figurcs are regrouped/rearranged wherecver necessary, to make them comparable. 3.The financial result for the Quarter cnded on 30-06-2026 has becn prepared in accordance with the IND-AS specified under section 133 of the companies Act and rules made thercunder 4. The IND-AS regarding segment reporting is not applicable to the company. By order of the Boay (Bhawani § Goyal Managing Dircctor DIN No. 03255804 P Dl aa tc ee. : A 13h -m 0e 8d -a 2b 0a 26d ‘ MW aa hr ed n dN ro a- g a0 r3, h ,N a Hn ag ra yl a nC ah -a 1u 2d 3h 0r 2y 3, Namaul, Reg. Off.: 310, Wall Street-1, Near Gujarat College Cross Road, Ellisbridge Ahmedabad-380006, GJ, Ph.: 8711811163 CIN: L93000G)1895PLC025276, Email: investors opl@gmail com, Website: www.omkarpharmachem,co in